Spotlight: Dr. Shiva Jayaraman on NeoPancONE and building a first-class pancreatic cancer care program at St. Joseph’s Health Centre By Ali Schofield As hospitals across the country regain capacity amid the Covid-19 pandemic, more NeoPancONE participating trial...
Today I am thrilled to announce the launch of our next landmark research investment, PASS-01: a clinical trial that will finally address the diverse nature of this disease and provide personalized treatment options for advanced pancreatic cancer patients. For over 40...
For several months the COVID-19 crisis has caused many research projects to slow, but Pancreatic Cancer Canada’s research program has not been idle. We have taken this time to quietly prepare for our next big project, because even in the midst of...
Pancreatic Cancer Clinical Trial Launches During Pandemic With Aim to Change Standard of Care for Patients TORONTO, ON, July 15, 2020 – Pancreatic Cancer Canada announced today the launch of NeoPancONE, a Phase II clinical trial that aims to be a curative strategy for...
PCC Funded COMPASS Trial Leads to the Discovery of Five New Subtypes of Pancreatic Cancer We are excited to share the recent success of the COMPASS trial, a research study funded in part by Pancreatic Cancer Canada, that has announced the discovery of five distinct...
2018 Research Investments After investing in genetic sequencing in 2017, we realized we were just scratching the surface: both in terms of our understanding of pancreatic cancer subtypes, but also in the ways that personalized medicine – which involves treatment...
Recent Comments